Rocket Pharmaceuticals, Inc.
A developer of gene therapies for rare, life-threatening genetic diseases, Rocket Pharmaceuticals works to correct the underlying genetic defects behind conditions like Danon disease and leukocyte adhesion deficiency. Founded in 2015 and merged with Inotek Pharmaceuticals in 2018, the company's name reflects its "moonshot" ambition to bring speed to medicine. Its therapies either modify a patient's own blood stem cells outside the body or deliver corrected genes directly via engineered viruses.
Bought 1.36M
Granted 47.7K
Granted 630.6K · Bought 42.0K · Sold 179.4K
Granted 157.8K · Bought 21.1K · Sold 30.9K
Granted 49.4K · Sold 309.0K
Granted 680.9K · Sold 48.7K
Granted 469.1K
Granted 407.9K
Granted 168.9K · Sold 172.2K
Granted 125.9K · Sold 17.6K
Granted 129.6K · Sold 80.0K
Granted 137.1K · Sold 9.0K
Granted 130.8K · Sold 77.0K
Granted 87.8K · Sold 18.6K
Granted 54.7K
Granted 53.3K
Granted 30.0K · Bought 20.0K
Granted 30.0K
Granted 30.0K
Granted 30.0K
Granted 30.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Wong Roderick +1 co-filerDirector, 10% owner, See remarks, Director, 10% owner, See Remarks · 12 transactions | — | 18.30M | — | 1.36M | — |
| Wong RoderickDirector, 10% owner · 2 transactions | — | 18.24Mas of Jul 2025 | 47.7K | — | — |
| Shah GauravCEO · 32 transactions | +68.9% | 1.52M | 630.6K | 42.0K | 179.4K |
| Patel KinnariSee Remarks · 23 transactions | — | 1.12Mas of May 2025 | 157.8K | 21.1K | 30.9K |
| Makker GothamDirector · 6 transactions | — | 1.02Mas of Jul 2025 | 49.4K | — | 309.0K |
| Wilson MartinGeneral Counsel · 25 transactions | — | 678.0K | 680.9K | — | 48.7K |
| Stevens Christopher JamesChief Operating Officer · 2 transactions | — | 469.1K | 469.1K | — | — |
| Rizvi Syed Ali-aamirChief Medical Officer · 3 transactions | — | 407.9K | 407.9K | — | — |
| Schwartz Jonathan DavidSee Remarks · 20 transactions | +2516.9% | 299.1K | 168.9K | — | 172.2K |
| Chaudhuri SarbaniSee Remarks · 2 transactions | — | 267.5K | 125.9K | — | 17.6K |
| Southwell David PDirector · 8 transactions | — | 144.8Kas of Jul 2025 | 129.6K | — | 80.0K |
| Ondrey AaronChief Financial Officer · 4 transactions | — | 128.2Kas of Jul 2025 | 137.1K | — | 9.0K |
| Militello JohnSee Remarks · 51 transactions | — | 89.8K | 130.8K | — | 77.0K |
| White Mark AndrewSee Remarks · 5 transactions | — | 69.1Kas of Oct 2024 | 87.8K | — | 18.6K |
| Granadillo Pedro PDirector · 2 transactions | — | 54.7Kas of Jun 2025 | 54.7K | — | — |
| Fong PeterDirector · 2 transactions | — | 53.3K | 53.3K | — | — |
| Bjork ElisabethDirector · 3 transactions | — | 50.0K | 30.0K | 20.0K | — |
| Dolsten MikaelDirector · 2 transactions | — | 44.2Kas of Jun 2025 | 30.0K | — | — |
| Boess CarstenDirector · 1 transaction | — | 30.0Kas of Jun 2025 | 30.0K | — | — |
| Malik Fady IbrahamDirector · 1 transaction | — | 30.0Kas of Jun 2025 | 30.0K | — | — |
| Pratumsuwan PiratipDirector · 1 transaction | — | 30.0Kas of Jun 2025 | 30.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +496.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.